This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria)

Condition	Treatment or Intervention	Phase
Neutropenia Fever Gram-Positive Bacterial Infections Neoplasms	Drug: Antibiotic  Drug: Vancomycin	Phase III

Ages Eligible for Study:  13 Years and above,  Genders Eligible for Study:  Both

Criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

• Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
• Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.

Exclusion Criteria:

• Patients with fever due to known causes.
• Patients with HIV.
• Patients with recent bone marrow transplant.
• Patients with an infected indwelling catheter that cannot be removed.
• Patients who have received more than one day of another antibiotic before entering the trial.
• Patients with endocarditis, osteomyelitis, meningitis, CNS infections.

California
      Research Center, San Diego,  California,  92134,  United States
      Research Center, Los Angeles,  California,  90033,  United States
      Research Center, Orange,  California,  92868,  United States
Florida
      Research Center, Miami,  Florida,  33136,  United States
Illinois
      Research Center, Springfield,  Illinois,  62701,  United States
      Research Center, Maywood,  Illinois,  60153,  United States
Kentucky
      Research Center, Lexington,  Kentucky,  40536,  United States
Massachusetts
      Research Center, Worcester,  Massachusetts,  01655,  United States
Michigan
      Research Center, Kalamazoo,  Michigan,  49001,  United States
New Jersey
      Research Center, Perth Amboy,  New Jersey,  08861,  United States
New York
      Research Center, Bronx,  New York,  10467-2490,  United States
Ohio
      Research Center, Youngstown,  Ohio,  44501,  United States
Tennessee
      Research Center, Jackson,  Tennessee,  38301,  United States
Texas
      Research Center, Houston,  Texas,  77030-4211,  United States
      Research Center, Houston,  Texas,  77030,  United States
Virginia
      Research Center, Richmond,  Virginia,  23249,  United States
      Research Center, Falls Church,  Virginia,  22042,  United States
      Research Center, Richmond,  Virginia,  23294,  United States
Washington
      Research Center, Tacoma,  Washington,  98405,  United States
Wisconsin
      Research Center, Milwaukee,  Wisconsin,  53226,  United States
Puerto Rico
      Research Center, Hato Rey,  00985,  Puerto Rico

Study ID Numbers:  M/1260/0079
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  May 3, 2002
ClinicalTrials.gov Identifier:  NCT00035425
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08